The National University of Singapore’s Yong Loo Lin School of Medicine has announced a groundbreaking research collaboration with MitoQ New Zealand, aimed at exploring the potential of MitoQ® (mitoquinol mesylate) to support healthy ageing through targeted mitochondrial interventions. This partnership is set to deepen scientific understanding of how mitochondrial antioxidants might mitigate the biological effects of ageing, leveraging cutting-edge biomarkers and biological ageing clocks to evaluate efficacy more efficiently than traditional long-term studies.
Mitochondria, the energy-producing organelles found within nearly every human cell, account for up to 95% of the body’s energy supply, especially critical in organs with high metabolic demands such as the heart, brain, liver, and muscles. However, during the energy production process, mitochondria inherently generate free radicals—highly reactive oxygen species—that cause oxidative stress and damage cellular components over time. This oxidative damage is thought to underlie many age-related declines, manifesting as fatigue, cognitive deficits, immune compromise, and slowed physical recovery.
MitoQ® is a mitochondria-targeted antioxidant developed with the goal of neutralizing oxidative stress directly at its source, thereby preserving cellular function and resilience. Unlike conventional antioxidants that act broadly and often inefficiently, MitoQ® accumulates selectively within mitochondria, offering precise mitigation of mitochondrial oxidative damage. This targeted approach has already been supported by decades of research and clinical trials, amassing over 1,000 peer-reviewed publications and 29 clinical studies focusing on mitochondrial health and aging biology.
The collaborative research initiative between NUS Medicine and MitoQ New Zealand will meticulously evaluate existing clinical and preclinical evidence surrounding MitoQ®, while conducting novel trials to assess its impact on a range of biological ageing markers. The partnership was formalized with the signing of a Memorandum of Understanding (MOU) by MitoQ CEO Mahara Inglis and NUS Associate Professor Jan Gruber on May 4, 2026, at the Singapore-New Zealand Leadership Forum in Singapore—a testament to the strategic importance of health innovation within the broader Singapore–New Zealand Comprehensive Strategic Partnership.
At the heart of this research is the utilization of biological ageing clocks—advanced algorithmic tools that estimate an individual’s biological age based on molecular biomarkers rather than chronological time. One such tool, LinAge3, offers sophisticated predictions of long-term mortality risk, disease susceptibility, and physical as well as cognitive function by analyzing blood-based epigenetic and molecular data. These clocks enable rapid evaluation of health interventions, providing actionable data far more quickly than the decades-long longitudinal clinical trials traditionally required for ageing research.
The research will unfold over two distinct phases. The initial phase, slated from May to September 2026, involves retrospective analysis of blood samples from a prior three-month study with 150 participants known to have used MitoQ®. Using the LinAge3 clock and molecular profiling, researchers aim to detect changes in biological ageing markers attributable to MitoQ® supplementation. This phase will refine hypotheses and validate the utility of the clock in detecting subtle physiological shifts.
Commencing concurrently in July 2026, the second research phase will conduct a controlled clinical trial enrolling approximately 100 participants. This study combines self-reported questionnaires with comprehensive laboratory analyses encompassing epigenetic clocks, vascular health markers, and cognitive function assessments. Blood samples collected during this phase will be subjected to multilayered molecular analyses, enabling a deep dive into the mechanistic effects of MitoQ® at cellular and systemic levels. Completion of this phase is anticipated by December 2027.
Through this rigorous approach, the collaboration seeks not only to clarify MitoQ®’s efficacy in modulating markers of biological ageing but also to enhance precision nutrition strategies. Such approaches tailor supplement interventions based on individual molecular profiles, potentially revolutionizing personalized healthcare and longevity practices.
Associate Professor Jan Gruber, who leads this research, emphasizes the project’s alignment with Singapore’s strategic priorities surrounding healthy ageing, disease prevention, and extending productive longevity. By establishing a stronger evidence base on mitochondrial interventions, this work seeks to empower individuals with science-driven insights to make informed decisions on dietary supplements and health regimens, thereby contributing to the global scientific community’s understanding of ageing biology.
Dr. Siobhan Mitchell, Chief Scientific Officer at MitoQ New Zealand, underscores the foundational role of science in the company’s mission. She highlights that decades of research underpin MitoQ®’s development, signaling that mitochondria-targeted antioxidants could play a transformative role in extending healthspan by combating cellular ageing processes at their origin.
MitoQ®’s unique modus operandi contrasts conventional systemic antioxidants by targeting mitochondrial membranes where reactive oxygen species generation occurs. This precise targeting mitigates oxidative damage that accelerates telomere attrition, mitochondrial DNA mutations, and impaired bioenergetics, all hallmarks of cellular ageing. The collaboration aims to quantify how this biochemical intervention translates into meaningful clinical outcomes reflected in biological ageing clocks and functional health metrics.
Importantly, this partnership harnesses cutting-edge computational biology, employing algorithmic models that integrate multi-omic datasets—epigenomic, transcriptomic, and proteomic—to finely characterize molecular signatures of ageing. These integrated approaches provide a holistic view of organellar health, systemic inflammation, and metabolic resilience, which are critical to understanding the complexities of ageing beyond simplistic chronological paradigms.
The strategic timing and international nature of this collaboration underscore the rising global imperative to tackle ageing as a biomedical and societal challenge. With ageing populations worldwide exerting unprecedented pressures on healthcare systems, interventions that delay biological ageing could mitigate chronic disease burden and enhance quality of life at advanced ages, delivering substantial socio-economic benefits.
By combining NUS Medicine’s expertise in biochemistry and translational research with MitoQ New Zealand’s pioneering antioxidative compounds, this partnership exemplifies a convergence of academia and industry to advance longevity science. The expected outcomes promise to refine clinical trial methodologies in ageing research and foster innovation in the commercial development of mitochondrial-targeted therapeutics.
Ultimately, this research venture heralds a new frontier in ageing science, where mitochondria-targeted antioxidants like MitoQ® are evaluated not only for symptomatic relief but as agents that may genuinely slow or partially reverse biological ageing processes. The use of biologically-relevant, quantifiable ageing clocks as endpoint measures represents a paradigm shift that could accelerate the validation and optimization of healthspan-extending interventions.
Subject of Research: Mitochondria-targeted antioxidants and biological ageing
Article Title: MitoQ® and NUS Medicine Unite to Unlock the Secrets of Healthy Ageing through Mitochondrial Science
News Publication Date: May 4, 2026
Web References: https://www.sciencedirect.com/science/article/pii/S0891584914001099
References: Peer-reviewed publications and clinical trials related to MitoQ’s impact on mitochondrial health and ageing
Image Credits: MitoQ
